These services include specialized options tailored to various cancer types. The PSMA PET CT scan is designed for prostate ...

Clarity Pharmaceuticals (ASX:CU6) has seen the U.S. FDA fast-track its prostate cancer imaging compound for use in PET scans on patients with recurring prostate cancer. The stock jumped 4% in the ...

Advancements and Projections in the Global Radiopharmaceuticals Market: Insights, Trends, Opportunities, and Recent DevelopmentsNew York, J ...

Radiopharm Theranostics appears to be emerging from unloved status to that of a genuine contender in the red-hot ...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 27 years, gives his ...

Prostate cancer is rapidly emerging as a significant health challenge in China, with the incidence rate steadily rising.

This is just a sampling of medical advancements in 2024 chosen for their common presence in the American population. It is ...

David Livingston/Getty Images Since going public with his Stage 3 non-Hodgkin lymphoma diagnosis in November 2024, Dave ...

M1 disease detected with PSMA-PET in 46 percent of patients with high-risk, nonmetastatic hormone-sensitive prostate cancer.

These services include specialized options tailored to various cancer types. The PSMA PET CT scan is designed for prostate cancer detection, while the DOTA PET CT scan aids in identifying ...

Clarity Pharmaceuticals (ASX: CU6) ('Clarity' or 'Company'), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for ...